adlitterio66339

Circa adlitterio66339

Questo autore non ha riempito alcun dettaglio.
Finora adlitterio66339 ha creato 511 post nel blog.

22 07, 2021

Pamela Trillo Aliaga et al., Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis.

adlitterio663392022-10-21T09:25:41+02:00

18 07, 2021

Alessandro Parisi et al., Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study

adlitterio663392022-10-21T09:31:52+02:00

13 07, 2021

Valentina Angerilli et al., Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas

adlitterio663392022-10-21T09:34:55+02:00

1 07, 2021

Cristina Morelli et al., Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling

adlitterio663392022-10-14T12:26:31+02:00

30 06, 2021

Anello Marcello Poma et al., COVID-19 autopsy cases: detection of virus in endocrine tissues

adlitterio663392022-10-21T09:41:38+02:00

24 06, 2021

Serena Ammendola et al., H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology

adlitterio663392022-10-21T13:52:43+02:00

15 06, 2021

Debora Olioso et al., Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study

adlitterio663392022-10-21T14:02:52+02:00

18 05, 2021

Anna ianza et al., EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.

adlitterio663392022-10-14T12:28:55+02:00

14 05, 2021

Alessandro Dal Maso et al., Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.

adlitterio663392022-10-21T14:06:21+02:00

10 05, 2021

Enrico Berrino et al., High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients.

adlitterio663392022-10-21T14:12:17+02:00

Precedente 171819 Successivo